ChristinaRudaSeedDO

PubMed

• Refining the risk estimate for transfusion-transmission of occult hepatitis B virus.
  Seed CR, Kiely P, Hoad VC, Keller AJ> ;Vox Sang.. 2016-08-26
• Re-evaluating the residual risk of transfusion-transmitted Ross River virus infection.
  Seed CR, Hoad VC, Faddy HM, Kiely P, Keller AJ, Pink J> ;Vox Sang.. 2016-05-01
• The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components.
  Seed CR, Wong J, Polizzotto MN, Faddy H, Keller AJ, Pink J> ;Vox Sang.. 2015-07-01
• Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme.
  Seed CR, Maloney R, Kiely P, Bell B, Keller AJ, Pink J> ;Vox Sang.. 2015-02-01
• Compliance with the current 12-month deferral for male-to-male sex in Australia.
  Seed CR, Lucky TT, Waller D, Wand H, Lee JF, Wroth S, McDonald A, Pink J, Wilson DP, Keller AJ> ;Vox Sang.. 2014-01-01
• A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without uni...
  Seed CR, Kiely P> ;Vox Sang.. 2013-11-01
• Malaria antibody persistence correlates with duration of exposure.
  Faddy HM, Seed CR, Faddy MJ, Flower RL, Harley RJ> ;Vox Sang.. 2013-05-01
• Duration of Ross River viraemia in a mouse model--implications for transfusion transmission.
  Shang G, Seed CR, Gahan ME, Rolph MS, Mahalingam S> ;Vox Sang.. 2012-04-01
• International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009.
  Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum ...> ;Vox Sang.. 2012-01-01
• Deferral of males who had sex with other males.
  Benjamin RJ, Bianco C, Goldman M, Seed CR, Yang H, Lee J, Keller AJ, Wendel S, Biagini S, Murray J, Devine DV, Zhu Y, Turek P, Moftah FM, Kullaste R, Pillonel J, Danic...> ;Vox Sang.. 2011-11-01
• Malaria antibody testing of Australian blood donors.
  Cheng A, Seed CR, Ismay S, Keller AJ> ;Vox Sang.. 2011-02-01
• Assessing the safety and efficacy of a test-based, targeted donor screening strategy to minimize transfusion transmitted malaria.
  Seed, C. R.,Kee, G.,Wong, T.,Law, M.,Ismay, S.> ;Vox Sang.. 2009 Sep 12
• Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.
  Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, ...> ;Vox Sang.. 2005-05-01
• The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria.
  Seed CR, Cheng A, Davis TME, Bolton WV, Keller AJ, Kitchen A, Cobain TJ> ;Vox Sang.. 2005-02-01
• Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
  Hyland C, Seed CR, Kiely P, Parker S, Cowley N, Bolton W> ;Vox Sang.. 2003-07-01
• Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.
  Mison L, Seed CR, Margaritis AR, Hyland C> ;Vox Sang.. 2003-01-01
• Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.
  Correll PK, Law MG, Seed CR, Gust A, Buring M, Dax EM, Keller AJ, Kaldor JM> ;Vox Sang.. 2001-07-01
• Join now to see all